Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-APRIL (mouse), mAb (blocking) (Centotto-1) (preservative free)

Method: A) Immunofluorescence of IgA-positive plasma cells (pink) and DAPI-positive nuclei (blue) in gut jejunum sections of 10-week-old wild type C57/Bl6 mice treated with 4 weekly i.p. injections of the indicated antibodies at 2 mg/kg. B) Quantification of IgA-positive plasma cells in the gut (average of 2 sections/mouse) of mice treated with Isotype control (n=5), or with anti-APRIL Centotto-1 (n=5), or with anti-BAFF Sandy-2 (n=4) or with both Centotto-1 and Sandy-2 (n=5). One way ANOVA with Dunnett’s multiple comparison test. ns: not significant. **** P<0.0001. Picture courtesy of Dr Mahya Eslami, Dr Pascal Schneider Lab, University of Lausanne, Switzerland
Product Details | |
---|---|
Synonyms | A Proliferation Inducing Ligand; Tumor Necrosis Factor Ligand Superfamily Member 13; TNFSF13; TALL-2; CD256 |
Product Type | Monoclonal Antibody |
Properties | |
Clone | Centotto-1 |
Isotype | Mouse IgG1κ |
Source/Host | Purified from concentrated hybridoma tissue culture supernatant. |
Immunogen/Antigen | Recombinant mouse APRIL. |
Label/Conjugates | Preservative Free |
Application |
Functional Application: Depletion of mouse APRIL. |
Crossreactivity | Mouse |
Specificity |
Recognizes mouse recombinant and endogenous APRIL. |
Purity | ≥95% (SDS-PAGE) |
Purity Detail | Protein G-affinity purified. |
Endotoxin Content | <0.01EU/μg purified protein (LAL test). |
Concentration | 1mg/ml |
Formulation | Liquid. In PBS. |
Isotype Negative Control | |
Other Product Data |
Note: BAFF and APRIL contribute to maintaining IgG, IgA, and IgM plasma cells in the bone marrow (BM), spleen, and intestine and rely mainly on three ligand/receptor pairs: APRIL-BCMA, BAFF-TACI, and APRIL-TACI. Together, these actors account for 90% of circulating antibodies. To efficiently target plasma cells, dual inhibition of BAFF (using blocking anti-BAFF (mouse), mAb (Sandy-2) (Prod. No. AG-20B-0063)) and APRIL (using blocking anti-APRIL (mouse), mAb (blocking) (Centotto-1) (Prod. No. AG-20B-0083PF) both developed at AdipoGen Life Sciences are required in a recently published study (see also Figure). |
Accession Number | Q9D777 |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
APRIL is a secreted cytokine, belonging to the TNF superfamily that binds to transmembrane activator and CAML interactor (TACI), B cell maturation antigen (BCMA) and can interact with carbohydrate side chains of heparan sulfate proteoglycans (HSPG) that may trigger cross-linking. APRIL maintains B cell homeostasis by acting at a later stage, modulating the function and survival of antigen-experienced B cells. APRIL (as well as BAFF) stimulates class-switch recombination (CSR), hence contributes to shaping humoral effector mechanisms. With regards to humoral memory, APRIL is involved in the establishment and survival of the long-lived plasma cell (LLPC) pool in the bone marrow (BM). Recently, APRIL has been shown to confer atheroprotection via binding to heparan sulfate (HS) chains of heparan-sulfate proteoglycan 2 (HSPG2), which limits LDL retention, macrophage accumulation and necrotic core formation. BAFF and APRIL are implicated in several human autoimmune diseases with autoreactive B cell involvement, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), IgA nephropathy (IgAN), and rheumatoid arthritis (RA). APRIL might also function in enhancing the proliferation of some tumor cells, especially B cell malignancies. BAFF and APRIL contribute to maintaining IgG, IgA, and IgM plasma cells in the bone marrow (BM), spleen and intestine and rely mainly on three ligand/receptor pairs: APRIL-BCMA, BAFF-TACI, and APRIL-TACI. APRIL plays an important role in B cell survival and proliferation, so blocking it can modulate immune responses. APRIL blocking antibodies can be useful for vaccine research, particularly to assess how APRIL inhibition affects normal immune responses to vaccination.
- APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans: D. Tsiantoulas, et al.; Nature 597, 92 (2021)
- BAFF, but not APRIL, initiates Chronic Lymphocytic Leukemia by inducing tumor-promoting genes rather than cell survival: F. Mackay, et al.; ahead of print (2023)
- An unappreciated cell survival-independent role for BAFF initiating chronic lymphocytic leukemia: M.A. Ullah, et al.; Front. Immunol. 15, 1345515 (2024)
- Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL and IL-6 in supporting antibody-producing cells in different tissues: M. Eslami, et al.; PNAS 21, e2404309121 (2024)